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Abstract
Background: Concerns have been raised over the safety of methylphenidate (MPH), with regard to adverse effects
on growth and blood pressure. Our study investigates whether, and to what extent, methylphenidate use in boys
with ADHD is associated with having low body mass index (BMI), having low height, and increased systolic and
diastolic blood pressure.
Methods: Data used for this study stem from the German KiGGS dataset. Three different groups of boys aged 6–15 years
were included in the analysis: ADHD patients who used MPH for less than 12 months; ADHD patients who used MPH for
12 months or more; and ADHD patients without current MPH treatment. Each of these three groups was compared to a
non-ADHD control group regarding low weight (BMI≤ 3rd percentile), low height (≤3rd percentile) and raised systolic
and diastolic blood pressure. For growth outcomes, boys were categorized according to age (< 11 years/≥11 years, to
account for pubertal maturation). Multivariable logistic regression was conducted to test for associations.
Results: 4244 boys were included in the study; MPH < 12 months: n = 65 (n = 36 < 11 years), MPH ≥ 12 months:
n = 53 (n = 22 < 11 years), ADHD controls: n = 320 (n = 132 < 11 years), non-ADHD controls: n = 3806 (n = 2003
< 11 years). Pre-pubertal boys with MPH use less than 12 months and pubertal/postpubertal boys with MPH
use of 12 months or greater were significantly more likely to have a BMI ≤ 3rd percentile compared to non-
ADHD controls. Boys from the ADHD control group were significantly less likely to have a raised systolic
blood pressure compared to non-ADHD controls. Beyond that, no significant between group differences were
observed for any other growth and BP parameter.
Conclusion: The analyses of the KiGGS dataset showed that MPH use in boys with ADHD is associated with
low BMI. However, this effect was only observed in certain groups. Furthermore, our analysis was unable to
confirm that MPH use is also associated with low height (≤3rd percentile) and changes in blood pressure.
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Background
Attention deficit hyperactivity disorder (ADHD) is charac-
terized by pervasive and impairing hyperactivity, inatten-
tion and impulsiveness [1]. The worldwide prevalence of
ADHD among school-aged children and adolescents is
around 5% [2, 3]. Methylphenidate (MPH), the most com-
monly prescribed psychopharmacological treatment of
ADHD in Europe, is effective at improving ADHD symp-
toms [4]. However, there have been reports in the litera-
ture concerning the effect of MPH on growth [5] and
adverse cardiovascular outcomes [6].
Height and weight
Effects on growth are usually reported as minor at the
group level, but there is wide variability with some chil-
dren unaffected [7–9] and others reporting moderate
growth suppression [10–12]. Longitudinal studies sug-
gest an overall height stunting of approximately 1 cm/
year during the first three years of treatment which can
be clinically relevant. These effects appear to attenuate
over time and terminal adult height is not necessarily re-
duced [5, 13]. A Cochrane review published in 2015 ex-
amined the literature on the beneficial and harmful
effects of methylphenidate on children and adolescents
with ADHD [14]. With respect to the effect of methyl-
phenidate on weight, five trials including 805 partici-
pants reported that children taking methylphenidate
weighed significantly less than controls and six trials
(859 participants) reported a decrease in weight among
children taking methylphenidate. Children were also
more likely to have a lower body mass index (BMI)
based on the findings from one study with 215 partici-
pants [14]. However, disentangling these effects from
growth deficits that may be associated with ADHD itself
is challenging [5, 10, 15–17].
Cardiovascular outcomes
A number of studies have investigated cardiovascular
events (e.g. stroke, myocardial infarction, ventricular
arrhythmia, sudden death) and cardiovascular effects
(e.g. changes in BP and heart rate) associated with MPH.
Dalsgaard et al. [18] conducted a prospective longitu-
dinal cohort study in Denmark (n = 714,258) to deter-
mine the risk of cardiovascular events among stimulant
users. They reported a stimulant-related increase in risk
for cardiovascular events (adjusted Hazard Ratio = 1.83
(1.10–3.04)) that persisted after restricting the analysis
to only children with ADHD (n = 8300) (adjusted Hazard
Ratio = 2.20 (2.15–2.24)).
A pooled analysis of three large data sets (19–21) in-
cluding more than 1.8 million patients (ages 2–24 years
[19], 25–64 years [20], 3–17 years [21]) reported no as-
sociation between methylphenidate, amphetamine
(AMP) and atomoxetine and sudden death or stroke
(adjusted Odds Ratio = 0.93 (0.731.17)) [22]. However, in
the study by Cooper et al. [19], it was reported that
while there was no evidence of an association of serious
cardiovascular events with ADHD drug use identified
(adjusted Hazard Ratio = 0.70 (0.31–1.85)), “the upper
limit of the 95% confidence interval indicated that a
doubling of the risk could not be ruled out. However,
the absolute magnitude of such an increased risk would
be low”. A population-based, retrospective cohort
study, conducted by Winterstein et al. [23], reported
no significant association between central nervous
stimulants and cardiovascular events (stroke, acute
myocardial infarction and sudden cardiac death as a
primary composite endpoint and the previous events
plus ventricular arrhythmia as a secondary composite
endpoint (adjusted Odds Ratio = 0.62 (0.27–1.44) and
0.74 (0.38–1.46) for the primary and secondary end-
points respectively [23]).
In terms of cardiovascular effects, stimulant medica-
tion can cause small increases in heart rate and BP. On
average, heart rate increases of 1–2 beats per minute are
reported at the group level, although larger increases
can occur in some individuals. Average increases in sys-
tolic and diastolic BP range between 1 and 4 mmHg and
1 and 2 mmHg respectively [24]. Few studies report cat-
egorical hypertension data (defined as BP beyond the
95th centile) although anecdotally and from case reports,
it is reported that MPH can cause a rise in BP above the
95th centile in some individuals [25].
The Committee for Medicinal Products for Human
Use at the European Medicines Agency concluded in
January 2009 that the overall benefits of MPH outweigh
the risks; at the same time they highlighted the need for
more data on the long-term effects of MPH on children
and young adults as many of the trials conducted to date
had focused only on short-term effects [26].
The aim of this study was to examine associations be-
tween MPH use in ADHD, body mass index (BMI) and
height and BP in boys. Data from the German Health
and Examination Survey for Children and Adolescents
(KiGGS), a population-based German representative
sample, were analyzed to evaluate the hypothesis that
boys with ADHD and current MPH use show higher
percentages of having low BMI, having low height, and
of increased systolic blood pressure (SBP) and diastolic
blood pressure (DBP) compared to controls.
Methods
Data source
Data for the present study stem from the KiGGS data-
base. KiGGS was conducted by the Robert Koch Insti-
tute, Berlin, Germany, between May 2003 and May
2006. A two-stage sampling strategy was utilised: in the
first stage, a representative sample of 167 German
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municipalities was identified. In the second stage, ran-
dom samples of children and adolescents aged between
0 and 17, and stratified by sex and age, were then se-
lected from these municipalities through local popula-
tion registries. The resulting sample included 17,461
children and adolescents (8985 boys, 8656 girls). De-
tailed information on the KiGGS dataset and the sam-
pling strategy have been reported elsewhere [27, 28].
Sample selection
Individuals were classified as having ADHD if a parent
reported that a diagnosis of ADHD had been made by a
physician or psychologist [29]. Current
ADHD-medication use (defined as use of medication
within the seven days prior to interview) was docu-
mented using a standardized computer-assisted personal
drug use interview which was conducted with the partic-
ipants and their parents by a study physician [29]. The
study design ensured that the study subjects were not
interviewed during school holidays to exclude discon-
tinuity of ADHD medication due to school breaks [30].
Duration of current medication use was categorized as
either: less than 12 months or 12 months and longer.
Patients with a record of current AMP use were ex-
cluded from the analyses in line with this study’s aim to
focus on methylphenidate exclusively. Information on
past use of medication was not recorded in the database.
Patients who did not have a value recorded for a particu-
lar outcome variable (BMI, height, systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP)) were
excluded from that specific variable analysis.
Four groups of individuals were identified for inclusion
in the study: two groups who were taking MPH (<
12 months and ≥ 12 months), an ADHD group not cur-
rently taking MPH and a non-ADHD control group.
Matching of controls to the medicated cohort was not
undertaken. Preliminary analyses revealed that there
were low numbers of females and older adolescents
amongst the ADHD groups generally and the MPH
groups specifically and so the study was restricted to
males aged between 6 and 15 years inclusive.
Outcome variables/ assessments
BMI, height: Body weight was measured in underwear to
the nearest 0.1 kg with a calibrated scale (SECA, Bir-
mingham, UK). Body height was measured by trained
staff according to a standardized protocol to the nearest
0.1 cm using portable devices (standing height with Har-
penden stadiometer for ages 2–17; Holtain Ltd., Cry-
mych, UK). Measurement procedures were subject to
internal and external quality control measures [31]. BMI
was calculated as the ratio of weight (kg) to height (m)
squared [31].
BP: Two readings of SBP and DBP were obtained
using an automated oscillometric device (Datascope
Accutorr Plus) at 2-min intervals after a non-strenuous
part of the examination and an additional 5-min rest.
The measurements were taken using the right arm, in
the sitting position with the elbow at the level of the
right atrium, using 1 of 4 cuff sizes which had to cover
at least two-thirds of the upper arm length (from the ax-
illa to the ante-cubital fossa). The mean of the two mea-
surements was used for analysis [32]. The KiGGS
dataset included a variable cardiac disease (code ca07);
this variable, based on parents’ reports, was recorded in
the dataset as ‘yes’, ‘no’ or ‘don’t know’.
Outcome references
BMI and height
German reference data for BMI and height were obtained
[31, 33]. The main focus of the data analyses was the per-
centage of boys with low BMI, defined as BMI <3rd per-
centile and the percentage of boys with a height ≤ 3rd
percentile [34]. Analyses were conducted on the cohort as
a whole (from 6 to 15 years) as well as according to two
age categories, defined as 6–10 years and 11–15 years. By
splitting the sample according to age, we use a simplified
method that allows us to separate prepubertal children
from peri and pubertal boys in the analyses, thus amplify-
ing the power to detect an impact of MPH on growth.
BP
For the analysis of SBP and DBP, guidelines from the
European Society of Hypertension [35] were used since
these guidelines did not exclude overweight children un-
like German reference data. (32).
Definition and classification of hypertension was as
follows [35]:
Class SBP / DBP percentile
Normal <90th
High-normal ≥90th to < 95th
≥120/80 even if below 90th percentile in
adolescents
Stage 1 hypertension 95th percentile to the 99th percentile plus
5 mmHg
Stage 2 hypertension >99th percentile plus 5 mmHg
Both high-normal BP (≥90th to <95th percentile) and
hypertension (Stage 1 (95th percentile to the 99th per-
centile plus 5 mmHg) or Stage 2 hypertension (>99th
percentile plus 5 mmHg)) were collapsed to form
“Raised SBP” and “Raised DBP” categories for the pur-
poses of the regression analyses.
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Statistical methods
For each outcome variable, mean and standard
deviations (sd) was calculated. Odds Ratios (OR) and
95% Confidence Intervals (95% CI) were derived from
logistic regression analyses. Each of the three ADHD
groups was compared to a non-ADHD control group re-
garding weight (BMI ≤ 3rd percentile), height (≤3rd per-
centile) and raised SBP and DBP.
For the outcomes BMI and height, boys were
categorized according to age (< 11 years/≥11 years, to
account for pubertal maturation). The relationship
between blood pressure and MPH use was examined
using logistic regression adjusting for age, BMI and
cardiac disease. Sensitivity analysis was conducted
removing patients who had a cardiac disease code of yes
or don’t know.
A p-value of < 0.05 was considered significant for all
analyses.
Results
i) Sample characteristics:
A total of 4244 boys were included in the study: n = 65
in MPH < 12 months, n = 53 in MPH ≥ 12 months, n =
320 ADHD controls, and n = 3806 non-ADHD controls;
2193 (51.7%) boys of the total sample were 6–10 years
old, 2051 boys (48.3%) were aged 11–15 years. For
details see Table 1.
Body mass index
BMI data were available for 4229 boys (99.65%). Data of
the group of boys aged 6–10 years (n = 2185) and those
aged 11–15 years (n = 2044) were analyzed separately.
The focus of the analyses was the percentage of boys
who had low BMI, defined as BMI ≤ 3rd percentile. In
the group of boys aged 6–10 years, those with MPH use
of less than 12 months were significantly more likely to
have a BMI ≤ 3rd percentile compared to the
non-ADHD control group (OR 4.52 (95% CI, 1.54–
13.28), p = 0.006). Whereas in the subsample of boys
aged 11–15 years, those with MPH use ≥12 months were
significantly more likely to have a BMI ≤ 3rd percentile
compared to the non-ADHD control group (OR 3.59
(1.06–12.22), p = 0.040). Moreover, when compared to
the non-ADHD control group no significant differences
with regard to low weight were observed for the other
groups (see Table 2).
Height
Height data were available for 4242 boys (99.95%). In
accordance with the analysis of the BMI data we
distinguished between boys aged 6–10 years and 11–
15 years. In both age-groups, no significant differences
between the MPH and ADHD control groups and the
non-ADHD control group were observed with regard to
the percentage of boys with a height ≤ 3rd percentile
(see Table 3).
Blood pressure
Blood pressure data were available for 4238 boys
(99.86%). Mean SBP and mean DBP were similar across
the different groups. Stage 2 hypertension based on SBP
and/or DBP was generally very rare and was not
observed in boys currently taking MPH. However, stage
1 hypertension based on SBP and/or DBP could be
observed most frequently in those taking MPH ≥
12 months (for details see Table 4). The percentage of
boys in the ADHD control group with raised SBP was
statistically significantly lower than in the non-ADHD
control group (OR 0.65 (95% CI 0.46–0.92), p = 0.016).
Moreover, no statistically significant differences between
the MPH groups and ADHD control groups and the
non-ADHD control group with regard to raised SBP nor
to raised DBP could be found (See Table 5). These find-
ings persisted after removal of such patients with a car-
diac disease code of yes or don’t know.
Discussion
This study investigated naturalistic data from a cohort of
children collected within a large nation-wide survey in
Germany. The aim of this study was to explore growth
and cardiovascular outcomes across different patient
groups, in particular to evaluate the hypothesis that boys
with ADHD and current MPH use show a higher per-
centage of having low BMI, having low height, and in-
creased systolic and diastolic BP compared to controls.
Height and BMI
Our analysis was unable to confirm our hypotheses that
MPH use is also associated with low height (height ≤ 3rd
percentile).
Table 1 Number (%) of boys in each study cohort
MPH < 12 months MPH≥ 12 months ADHD control Non-ADHD control Total (n)
Boys 6–10 years (n / %) 36 (0.85) 22 (0.52) 132 (3.11) 2003 (47.20) 2193
Boys 11–15 years (n / %) 29 (0.68) 31 (0.73) 188 (4.43) 1803 (42.48) 2051
Total (n / %) 65 (1.53) 53 (1.25) 320 (7.54) 3806 (89.68) 4244
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Several studies in children with ADHD have
investigated associations between ADHD medication
and height. Hanć and colleagues reported that the
height of drug-naïve boys with ADHD was not signifi-
cantly different from the norm [17]. Zhang and col-
leagues examined the impact of long-term treatment of
MPH on height and weight of school age children with
ADHD and reported a small but significant deceleration
of height velocity, the magnitude of which was related to
the duration of treatment [36].
Our analyses of the KiGGS dataset overall showed that
MPH use in boys with ADHD was associated with low
BMI. This effect was observed in the younger boys aged
6–10 years with MPH use of less than 12 months (OR:
4.52, 95% CI: 1.54–13.28, p = 0.006). There was a trend
towards an effect in the boys aged 11–15 years with MPH
use ≥12 months (OR: 3.59, 95% CI: 1.06–12.22, p = 0.04).
Boys aged 6–10 years with MPH use ≥12 months and
boys 11–15 years with MPH use less than 12 months did
not significantly differ from the non-ADHD control group
in that respect. Several considerations might help to inter-
pret these findings:
A fast weight lost within a short amount of time
(weeks or months) can raise concerns and lead to
discontinuation of medication (in particular in younger
children). This could explain why low BMI was more
often in boys 6–10 years of age with MPH use of less
than 12 months compared to controls, but not in the
group with an MPH use ≥12 months (as this sample was
reduced by the number of those who had to discontinue
due to earlier weight loss).
However, we found the opposite effect in pubertal/
post-pubertal boys. This might be due to a higher
proportion of slow weight loss resulting in low BMI after
more than one year of treatment. One reason for this
might be a less severe post-pubertal effect of MPH on
Table 2 BMI data for 4229 boys
BMI≤ 3rd percentile, n (%) MPH < 12 months
(n = 65)
MPH≥ 12 months
(n = 53)
ADHD control
(n = 317)
Non-ADHD control
(n = 3794)
Boys 6–15 years (n = 4229)
Yes 5 (7.69) 4 (7.55) 11 (3.47) 108 (2.85)
No 60 (92.31) 49 (92.45) 306 (96.53) 3686 (97.15)
OR (95% CI), p-value 2.84 (1.12–7.22) 0.028 2.79 (0.99–7.89) 0.053 1.23 (0.65–2.31) 0.523 Reference
Boys 6–10 years (n = 2185)
Yes 4 (11.11) 1 (4.55) 3 (2.29) 56 (2.81)
No 32 (88.89) 21 (95.45) 128 (97.71) 1940 (97.19)
OR (95% CI), p-value 4.52 (1.54–13.28), 0.006 1.83 (0.24–14.04), 0.561 0.84 (0.26–2.71), 0.766 Reference
Boys 11–15 years (n = 2044)
Yes 1 (3.45) 3 (9.68) 8 (4.30) 52 (2.89)
No 28 (96.55) 28 (90.32) 178 (95.70) 1746 (97.11)
OR (95% CI), p-value 1.20 (0.16–8.98), 0.860 3.59 (1.06–12.22)
0.040
1.51 (0.71–3.23), 0.289 Reference
Table 3 Height data for 4242 boys
Height≤ 3rd percentile, n (%) MPH < 12 months (n = 65) MPH≥ 12 months (n = 53) ADHD control (n = 319) Non-ADHD control (n = 3805)
Boys 6–15 years (n = 4242)
Yes 2 (3.08) 3 (5.66) 11 (3.45) 104 (2.73)
No 63 (96.92) 50 (94.34) 308 (96.55) 3701 (97.27)
OR (95% CI), p-value 1.13 (0.27–4.68) 0.866 2.10 (0.64–6.85) 0.219 1.25 (0.67–2.36) 0.483 Reference
Boys 6–10 years (n = 2191)
Yes 2 (5.56) 2 (9.09) 3 (2.29) 53 (2.65)
No 34 (94.44) 20 (90.91) 128 (97.71) 1949 (97.35)
OR (95% CI), p-value 2.22 (0.52–9.53), 0.282 3.94 (0.88–17.62), 0.073 0.88 (0.27–2.86), 0.830 Reference
Boys 11–15 years (n = 2051)
Yes 0 (0.00) 1 (3.23) 8 (4.26) 51 (2.83)
No 29 (100.00) 30 (96.77) 180 (95.74) 1752 (97.17)
OR (95% CI), p-value - 1.19 (0.16–8.95), 0.863 1.55 (0.72–3.32), 0.260 Reference
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weight either due to metabolic reasons or due to a better
way of coping with reduced appetite in this age group
(eating larger meals in the later evening). These findings
should be interpreted with caution due to the small
numbers and wide confidence intervals and further
research is required to verify these considerations.
The relationships between ADHD, methylphenidate
use and growth appear to be complex. Some evidence
suggests that there is a significant association between
ADHD per se and obesity/overweight among patients,
however this relationship is not consistent across studies
[37]. Schwartz and colleagues used longitudinal health
record data to examine associations between ADHD
diagnosis and stimulant use on BMI trajectories
throughout childhood and adolescence [15]. Their
findings suggested that ADHD during childhood not
treated with stimulants was associated with higher
childhood BMIs whereas BMI was reduced in those
whose ADHD was treated with stimulants but for this
group there was a rebound later in adolescence to levels
above those for children without stimulant use or
without a history of ADHD [15]. Taking into account
findings for both parameters (height and BMI) our data
suggests that MPH may have more of an effect on
weight than on height, a finding also highlighted by
previous studies [10, 38].
Cardiovascular outcomes
Our analyses of the KiGGS dataset were unable to
confirm the hypotheses that MPH use in boys with
ADHD is associated with increased systolic and/or
diastolic BP (≥90th percentile).
A review of the cardiovascular effects associated with
MPH published in 2014 reported that changes in BP
across the eight included studies (n = 970) ranged from
− 4.3 to + 21.2 mmHg for mean SBP, and − 4.7 to +
4.0 mmHg for mean DBP. When duration of treatment
was examined, the authors concluded that short-term
use (≤6 months) of MPH was associated with small
increases in BP that were not statistically significant
whereas the data for MPH ≥ 6 months’ duration pro-
vided “a more mixed picture ...with some decreases in
SBP and DBP… reported. However, it should be noted
that these longer-term results were not corrected for
age” [39].
Clinicians need to be cognisant however of the effects
that even small changes in BP can have. Meta-analytic
data from adult studies at ages 40–69 years estimate that
each difference of 20 mmHg in usual SBP or 10 mmHg
in DBP is associated with a two-fold increase in the rate
of death from ischaemic heart disease and other vascular
causes and more than a two-fold increase in the death
rate from stroke [40]. In children, the exact level and
duration of elevated BP that causes target organ damage
are not established. However, there is increasing
Table 4 Blood Pressure data for 4238 boys
MPH < 12 months (n = 65) MPH≥ 12 months (n = 53) ADHD control (n = 318) Non-ADHD control (n = 3802)
i) Mean SBP (SD) / mmHg 107.71 (9.43) 107.23 (9.48) 107.71 (10.75) 108.61 (11.02)
ii) SBP Category
Normal, n (%) 53 (81.54) 45 (84.91) 273 (85.85) 3142 (82.64)
Normal-high, n (%) 8 (12.31) 3 (5.66) 27 (8.49) 328 (8.63)
Stage 1 hypertension, n (%) 4 (6.15) 5 (9.43) 17 (5.35) 308 (8.10)
Stage 2 hypertension, n (%) 0 (0.00) 0 (0.00) 1 (0.31) 24 (0.63)
iii) Mean DBP (SD) / mmHg 64.65 (5.75) 67.19 (7.38) 64.86 (7.51) 65.31 (7.44)
iv) DBP Category
Normal, n (%) 62 (95.38) 46 (86.79) 292 (91.82) 3494 (91.90)
Normal-high, n (%) 3 (4.62) 3 (5.66) 21 (6.60) 197 (5.18)
Stage 1 hypertension, n (%) 0 (0.00) 4 (7.55) 5 (1.57) 100 (2.63)
Stage 2 hypertension, n (%) 0 (0.00) 0 (0.00) 0 (0.00) 11 (0.29)
Table 5 Multivariable logistic regression for SBP and DBP,
adjusting for age, bmi and cardiac disease (n = 4225)
OR (95% CI) Std Err P-value
Normal SBP (base outcome)
Raised SBP
MPH < 12 months 1.09 (0.56–2.12) 0.37 0.796
MPH ≥12 months 0.91 (0.41–1.99) 0.36 0.807
ADHD Control 0.65 (0.46–0.92) 0.12 0.016¥
Non-ADHD Control Reference
Normal DBP (base outcome)
Raised DBP
MPH < 12 months 0.55 (0.17–1.77) 0.32 0.315
MPH ≥12 months 1.80 (0.80–4.06) 0.75 0.159
ADHD Control 0.88 (0.57–1.35) 0.19 0.554
Non-ADHD Control Reference
¥ significant
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evidence that even very small elevations in BP can have
long-term adverse effects on vascular structure and
function [41].
Limitations
There are a number of limitations which should be
considered in the current study. This study is
cross-sectional in nature and thus inferences of causality
cannot be made. For example, confounding factors (e.g.
genes) may influence the likelihood of being treated via
symptom severity and also influence body weight.
Follow-up data were not available which would be particu-
larly important for assessment of growth trajectories in
children. However, analyses of growth outcomes were
conducted stratified by age (< 11 years and ≥ 11 years) to
account for the correlation between height velocity,
growth spurts and pubertal maturation. The ADHD con-
trol group consists of children with an ADHD diagnosis
but no current use of MPH. However, data were not avail-
able as to whether these children were stimulant-naïve or
had prior exposure to MPH. The data were not gathered
for the primary purpose of investigating the current re-
search question and such secondary analyses cannot
gather additional data on prior exposure to MPH; it is ac-
knowledged that this potential contamination effect may
attenuate differences among the groups. Information on
dosing of MPH was not complete for all patients and,
therefore, could not be included in the analyses. Identify-
ing the ADHD cohort within the KiGGS sample was done
by parent report of an ADHD diagnosis that had been
made by a physician or psychologist. Due to the large
number of children included and the wide range of com-
peting physical, psychological and social health indicators
which comprised the dataset, a full psychiatric diagnostic
interview was not possible. However, other studies which
have examined prevalence of ADHD in the KiGGS cohort
have obtained a rate of 4.8% which is well in line with
other population-based estimates [42]. The numbers of
children within the two MPH groups were low and thus
this may have contributed to a lack of precision around
the estimates reported and the potential for Type II errors
should be considered. Selection bias may be an issue
within the MPH ≥ 12 months group insofar as individuals
in whom adverse effects emerge may be less likely to per-
sist with MPH treatment in the long-term. Finally, al-
though the original study sample was assessed over ten
years ago and the total number of children and adoles-
cents in Germany decreased since then (as in many West-
ern countries), we do not feel that this impacts on the
findings of the current study.
Conclusion and implications for practice
When looking at the balance between risks and benefits
of MPH treatment for ADHD, it needs to be considered
that ADHD itself is associated with a broad range of
psychosocial impairments such as; school failure,
parental and family conflict, social rejection by peers,
low self-esteem, higher risk for delinquent behaviour,
smoking and substance use disorders. Adverse outcomes
continue into adolescence and adulthood to include aca-
demic and vocational underachievement, reduced occu-
pational functioning, emotional dysregulation, anxiety,
depression, unemployment and suicide attempts, higher
rates of traffic accidents, unwanted pregnancies, preterm
mortality [43].
Secondly, findings from national registry studies indicate
that the use of medication, particularly stimulants, reduces
the risk of accidents and trauma-related emergency depart-
ment admissions and might have protective effects on sub-
stance abuse, suicidality and delinquent behaviour [44–46].
We have used cross-sectional data from a German na-
tional representative sample to identify adverse growth
and cardiovascular outcomes associated with MPH.
Effects on BMI were observed among the MPH cohorts;
clinicians should discuss with all patients and their par-
ents the potential effects on growth and balance these
effects with the outcomes of not treating ADHD symp-
toms. Particular attention should be paid to those
patients in the lower growth percentiles. Serious con-
cerns about growth warrant referral to a paediatric
endocrinologist or growth expert [24]. This study is also
one of the first to present categorical data on hyperten-
sion in patients taking MPH. While these data did not
highlight significant differences overall between MPH
cohorts and controls with respect to raised BP, the data
do not preclude clinically significant BP increases in sin-
gle cases, and so it is recommended to check BP and
pulse prior to initiating MPH treatment and to monitor
regularly throughout treatment. Sustained elevated BP
before or during MPH treatment requires assessment
and treatment. Further details on the management of
adverse effects of medication for ADHD are presented
by Graham and colleagues [24], Cortese and colleagues
[47] and the 2018 NICE Clinical Guideline [NG87] [4].
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